Most Post-Stroke Patients Miss Blood Pressure Targets in CONVINCE
A secondary analysis of a large contemporary secondary-prevention trial quantifies the gap between guideline blood pressure targets and real-world achievement, underscoring the pharmacist's role in medication optimization and adherence.
Managing hypertension after stroke is crucial to prevent recurrence and improve patient outcomes. 70% of patients in the study did not meet the updated 2022 guideline target of SBP < 130 mmHg. A significant portion of patients failed to achieve recommended BP targets, highlighting the need for improved strategies in hypertension management post-stroke. New strategies are essential for effective post-stroke hypertension management.
📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report.
Authors:Synnott P, Walsh C, Weimar C, Purroy F, Price C, Fonseca AC, Hill M, Jatuzis D, Kõrv J, Kruuse C, Mikulik R, Nederkoorn P, Czlonkowska A, Fischer U, Nabavi DG, Harbison J, Cassidy T, O'Connor M, Iversen HK, Adie K, Lemmens R, Kelly PJ, CONVINCE investigators
Citation:Synnott P, Walsh C, Weimar C, et al. Contemporary achievement of guideline recommendations for blood pressure management after stroke in the CONVINCE trial. European stroke journal. 2026;11(7). doi:10.1093/esj/aakag051
Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.
Executive Summary
Study Design
Patient Population
Primary Outcomes
Secondary Outcomes & Safety Profile
Pharmacist Implications
Clinical Pearls
Limitations
Controversies & Evidence Gaps
Cost & Logistics
Want the full analysis?
Subscribe to PharmD Signal for unrestricted access to every deep analysis, plus PDF reports, GRADE evidence grades, and pharmacist implications for every article we publish.